FDA
-
-
-
-
-
-
-
Merck to acquire Verona Pharma for $10 billion to add COPD treatment
-
-
-
-
-
-
-
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
-
-
-
-
-
-
-
Innovative New COPD Maintenance Treatment Now Available Through DirectRx Specialty Pharmacy
-
-
-
-
-
-
-
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
-
-
-
-
-
-
-
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
-
-
-
-
-
-
-
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

